142 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
27 Feb 19
Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update
7:43am
trials in multiple solid tumors at the Q1 2019 earnings update call in May -
- Completed initial safety cohorts for ADP-A2M10 (MAGE-A10) in lung … at target doses of 1 billion cells (with doses up to 10 billion cells) -
- Completed Cohort 1 for safety in ADP-A2AFP (AFP) study and treating patients
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
13 Jan 20
Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership
8:42am
leading the ADP-A2AFP program in liver cancer as well as leading our safety and pharmacovigilance team over the last four years. I look forward … of Clinical Safety and Pharmacovigilance and leader of the ADP-A2AFP program since 2015. He has been acting Chief Medical Officer since August 2019. Prior
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
18 Jul 18
Other Events
5:01pm
Exhibit 99.1
Adaptimmune Announces Favorable Review of Safety from One Billion Cell Dose Cohort in
MAGE-A10 SPEAR T-cell Study and Initiation … to treat cancer, today announced favorable review of safety data from the second dose cohort of patients who received one billion transduced SPEAR T
8-K/A
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
27 Feb 19
CORRECTING and REPLACING — Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update
5:16pm
safety cohorts for ADP-A2M10 (MAGE-A10) in lung and triple tumor studies as well as ADP-A2M4 (MAGE-A4) basket study -
- Treating patients in expansion … phases of all ADP-A2M10 and ADP-A2M4 studies at target doses of 5 billion cells (with doses up to 10 billion cells) -
- Completed Cohort 1 for safety
8-K
EX-99.1
br2pz0xroz6qe5ga za
31 Oct 23
Adaptimmune Reports Positive Data with Lete-cel1 from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
8:07am
8-K
EX-99.1
86jf7
2 Apr 19
Other Events
8:10am
8-K
EX-99.1
b5duxo2
9 May 18
Adaptimmune Reports First Quarter 2018 Financial Results and Business Update
7:39am
8-K
EX-99.1
le6iid72dj2o2dw8m
19 May 21
Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial
5:08pm
8-K
EX-99.1
t76ycw oo9w4tqk
28 Aug 20
Regulation FD Disclosure
10:44am
8-K
EX-99.1
3rojhr2nq56u7jo783z
6 May 19
Adaptimmune TRANSFORMING T CELL THERAPY Clinical and Business Update
8:11am
8-K
EX-99.1
genw8j
15 Aug 18
Third Dosing Cohort to be initiated in MAGE-A4 SPEAR T-cell Basket Study After Favorable Review of Safety from One Billion Cell Dose Cohort
7:39am
8-K
EX-99.1
rqt9bcm2wuz e7s
6 May 19
Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors
7:08am
8-K
EX-99.1
whkos0mf ocoog8o
15 Oct 20
Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial
4:47pm
8-K
EX-99.1
vam46a6i9q32xs3ba
13 Sep 21
Other Events
7:08am
8-K
EX-99.1
ag5 151k3j
5 Nov 20
Adaptimmune Reports Q3 Financial Results and Business Update
7:40am
8-K
EX-99.1
sq3r3d05
7 Jan 19
Other Events
7:40am
8-K
EX-99.1
ry2ax94l 8xg
9 Nov 20
Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC
5:11pm
8-K
EX-99.1
ec0gman g1
4 Nov 21
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:40am